141 related articles for article (PubMed ID: 10530506)
1. Subchronic toluene exposure in low concentrations produces signs of reduced dysfunction in the 6-hydroxydopamine lesioned nigrostriatal dopaminergic system of the rat.
Cintra A; Aguirre JA; Andbjer B; Finnman UB; Hagman M; Agnati LF; Höglund C; Möller A; Fuxe K
Neurosci Lett; 1999 Oct; 274(1):5-8. PubMed ID: 10530506
[TBL] [Abstract][Full Text] [Related]
2. Subacute toluene exposure increases DA dysfunction in the 6-OH dopamine lesioned nigrostriatal dopaminergic system of the rat.
Cintra A; Andbjer B; Finnman UB; Hagman M; Agnati LF; Höglund G; Fuxe K
Neurosci Lett; 1996 Oct; 217(1):61-5. PubMed ID: 8905740
[TBL] [Abstract][Full Text] [Related]
3. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery.
Lapchak PA; Miller PJ; Collins F; Jiao S
Neuroscience; 1997 May; 78(1):61-72. PubMed ID: 9135089
[TBL] [Abstract][Full Text] [Related]
4. Morphological and biochemical adaptations to unilateral dopamine denervation of the neostriatum in newborn rats.
Penit-Soria J; Durand C; Herve D; Besson MJ
Neuroscience; 1997 Apr; 77(3):753-66. PubMed ID: 9070750
[TBL] [Abstract][Full Text] [Related]
5. The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway.
Ueki A; Rosén L; Andbjer B; Finnman UB; Altamimi U; Janson AM; Goldstein M; Agnati LF; Fuxe K
Exp Brain Res; 1993; 93(2):259-70. PubMed ID: 8098283
[TBL] [Abstract][Full Text] [Related]
6. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR
Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643
[TBL] [Abstract][Full Text] [Related]
7. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
8. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.
Farrand AQ; Helke KL; Gregory RA; Gooz M; Hinson VK; Boger HA
Brain Stimul; 2017; 10(6):1045-1054. PubMed ID: 28918943
[TBL] [Abstract][Full Text] [Related]
9. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions.
Quesada A; Micevych PE
J Neurosci Res; 2004 Jan; 75(1):107-16. PubMed ID: 14689453
[TBL] [Abstract][Full Text] [Related]
10. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.
Ahmad M; Saleem S; Ahmad AS; Yousuf S; Ansari MA; Khan MB; Ishrat T; Chaturvedi RK; Agrawal AK; Islam F
J Neurochem; 2005 Apr; 93(1):94-104. PubMed ID: 15773909
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
Matsuura K; Makino H; Ogawa N
Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Srinivasan J; Schmidt WJ
Eur J Neurosci; 2003 Jun; 17(12):2586-92. PubMed ID: 12823465
[TBL] [Abstract][Full Text] [Related]
13. Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study.
Balcioglu A; Zhang K; Tarazi FI
Neuroscience; 2003; 119(4):1045-53. PubMed ID: 12831863
[TBL] [Abstract][Full Text] [Related]
14. Altered melatonin MT
Kang NH; Carriere CH; Bahna SG; Niles LP
Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.
Han B; Hu J; Shen J; Gao Y; Lu Y; Wang T
Eur J Pharmacol; 2013 Aug; 714(1-3):83-8. PubMed ID: 23791614
[TBL] [Abstract][Full Text] [Related]
16. Left/right nigrostriatal asymmetry in susceptibility to neurotoxic dopamine depletion with 6-hydroxydopamine in rats.
Sullivan RM; Szechtman H
Neurosci Lett; 1994 Mar; 170(1):83-6. PubMed ID: 8041518
[TBL] [Abstract][Full Text] [Related]
17. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
18. Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat.
Henderson JM; Watson S; Halliday GM; Heinemann T; Gerlach M
Behav Brain Res; 2003 Feb; 139(1-2):105-13. PubMed ID: 12642181
[TBL] [Abstract][Full Text] [Related]
19. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
[TBL] [Abstract][Full Text] [Related]
20. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
